| The mouse light/dark box test M Bourin, M Hascoët European journal of pharmacology 463 (1-3), 55-65, 2003 | 1593 | 2003 |
| Forced swimming test in mice: a review of antidepressant activity B Petit-Demouliere, F Chenu, M Bourin Psychopharmacology 177, 245-255, 2005 | 1166 | 2005 |
| Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder M Berk, S Dodd, M Kauer‐Sant’anna, GS Malhi, M Bourin, F Kapczinski, ... Acta Psychiatrica Scandinavica 116, 41-49, 2007 | 483 | 2007 |
| The other face of depression, reduced positive affect: the role of catecholamines in causation and cure D Nutt, K Demyttenaere, Z Janka, T Aarre, M Bourin, PL Canonico, ... Journal of psychopharmacology 21 (5), 461-471, 2007 | 441 | 2007 |
| Animal models of anxiety in mice M Bourin, B Petit‐Demoulière, B Nic Dhonnchadha, M Hascöet Fundamental & clinical pharmacology 21 (6), 567-574, 2007 | 403 | 2007 |
| Dopamine, depression and antidepressants E Dailly, F Chenu, CE Renard, M Bourin Fundamental & clinical pharmacology 18 (6), 601-607, 2004 | 393 | 2004 |
| Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition B Bandelow, D Baldwin, M Abelli, B Bolea-Alamanac, M Bourin, ... The World Journal of Biological Psychiatry 18 (3), 162-214, 2017 | 366 | 2017 |
| Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4 J Fang, M Bourin, GB Baker Naunyn-Schmiedeberg's archives of pharmacology 359, 147-151, 1999 | 313 | 1999 |
| Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors M Bourin, E Mocaër, R Porsolt Journal of Psychiatry and Neuroscience 29 (2), 126-133, 2004 | 303 | 2004 |
| Paroxetine: a review M Bourin, P Chue, Y Guillon CNS drug reviews 7 (1), 25-47, 2001 | 297 | 2001 |
| The mouse ligth-dark paradigm: a review M Hascoët, M Bourin, BÁN Dhonnchadha Progress in Neuro-Psychopharmacology and Biological Psychiatry 25 (1), 141-166, 2001 | 292 | 2001 |
| 3, 4-Methylenedioxy analogues of amphetamine: defining the risks to humans KM Hegadoren, GB Baker, M Bourin Neuroscience & Biobehavioral Reviews 23 (4), 539-553, 1999 | 264 | 1999 |
| Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial E Vieta, M Bourin, R Sanchez, R Marcus, E Stock, R McQuade, W Carson, ... The British Journal of Psychiatry 187 (3), 235-242, 2005 | 252 | 2005 |
| Antidepressant-like effects in various mice strains in the tail suspension test N Ripoll, DJP David, E Dailly, M Hascoët, M Bourin Behavioural brain research 143 (2), 193-200, 2003 | 221 | 2003 |
| A new approach to the light/dark test procedure in mice M HascoëT, M Bourin Pharmacology Biochemistry and Behavior 60 (3), 645-653, 1998 | 219 | 1998 |
| Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity JP Redrobe, M Bourin, MC Colombel, GB Baker Psychopharmacology 138 (1), 1-8, 1998 | 217 | 1998 |
| Antidepressant-like effects in various mice strains in the forced swimming test DJP David, CE Renard, P Jolliet, M Hascoët, M Bourin Psychopharmacology 166, 373-382, 2003 | 209 | 2003 |
| Animal models for screening anxiolytic-like drugs: a perspective M Bourin Dialogues in clinical neuroscience 17 (3), 295-303, 2015 | 200 | 2015 |
| How valuable are animal models in defining antidepressant activity? M Bourin, AJ Fiocco, F Clenet Human Psychopharmacology: Clinical and Experimental 16 (1), 9-21, 2001 | 196 | 2001 |
| Antidepressant-and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice V Volke, G Wegener, M Bourin, E Vasar Behavioural brain research 140 (1-2), 141-147, 2003 | 194 | 2003 |
